middle.news
INOVIQ’s CAR-NK-Exosomes Slash Tumors by 61.5% in Breast Cancer Model
8:55am on Monday 22nd of December, 2025 AEDT
•
Healthcare
Read Story
INOVIQ’s CAR-NK-Exosomes Slash Tumors by 61.5% in Breast Cancer Model
8:55am on Monday 22nd of December, 2025 AEDT
Key Points
61.5% tumor reduction achieved with CAR-NK-exosomes
100% survival rate in treated mice over 28 days
No observable adverse effects, indicating strong safety profile
Reduced non-specific liver accumulation confirms precise tumor targeting
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inoviq (ASX:IIQ)
OPEN ARTICLE